Retrovirus, mycotoxins, immunosuppression and neurodegeneration;Retrovirus, micotoxinas, inmunosupresión y neurodegeneración

Revista de Neurologia

Volumn 35, Issue 6, 2002, Pages 562-571

  León Sarmiento, Fidias E ^a,c   Carpintero de Jimeno, M ^b  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b Lab Quimico de Monitoreo Ambiental   (Colombia)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

HIV; HTLV; Immunosuppression; Mycotoxins; Neurodegeneration; Retrovirus

Indexed keywords

MYCOTOXIN; NEUROTOXIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NERVE DEGENERATION; PATHOGENESIS; PUBLIC HEALTH; RETROVIRUS; REVIEW; RISK FACTOR; SJOEGREN SYNDROME; SPASTIC PARESIS; T CELL LEUKEMIA;

EID: 0344406996     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3506.2001490     Document Type: Review

References (224)

1. Temin H, Mizutami S. RNA-directed DNA polymerase in virions of Rous sarcoma virus. Nature 1970; 226: 1211-3.
2. Gallagher RE, Gallo RC. Type C RNA tumor virus isolated from cultured human acute myelogenous leukemia cells. Science 1975; 187: 350-3.
3. Barbacid M, Bolognesi D, Aaronson SA. Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. Proc Natl Acad Sci U S A 1980; 77: 1617-1.
4. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. The isolation of HIV: has it really been achieved? Continuum 1996; 4: 1-24.
5. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77: 7415-9.
6. Kalyanaraman VS, Cabradilla CD, Getchell JP, Narayanan R, Braff EH, Chermann JC, et al. A new subtype of human T-cell leukemia virus (human T-leukemia virus 11) associated with a T-cell variant of hairy cell leukemia. Science 1984; 225: 321-3.
7. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and all risk for AIDS. Science 1984; 224: 500-3.
8. Kanki PJ, Hopper JR, Essex M. The origins of HIV and HTLV-4/HIV2. Ann N Y Acad Sci 1987; 511: 370-5.
9. Manzari V, Gismondi A, Barillari G, Morrone S, Modesti A, Albonici L, et al. HTLV-V: a new human retrovirus isolated in a Tac-negative T-cell lymphoma/leukemia. Science 1987; 238: 1581-3.
10. Yoshida M, Miyoshi I, Inhuma Y. Isolation and characterization of retrovirus (ATLV) from cell lines of human adult T-cell leukemia and its implications in the disease. Proc Natl Acad Sci U S A 1982; 79: 2031-5.
11. Gallo R, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immunodeficiency syndrome. Science 1983; 220: 865-7.
12. Gessain A, Barin F, Vemant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-9.
13. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy: a new clinical entity. Lancet 1986; 1: 1031-2.
14. Lairmore PH, Jacobson S, Gracia F, De BK, Castillo L, Larreategui M, et al. Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Natl Acad Sci U S A 1990; 87: 8840-4.
15. Peters AA, Oger JJ, Coulthart MB, Waters DJ, Cummings HJ, Dekaban GA. An apparent case of human T-cell lymphotropic virus type II (HTLV-II)-associated neurological disease: a clinical, molecular, and phylogenetic characterisation. J Clin Virol 1999; 14: 37-50.
16. Brand A, Griffiths DJ, Herve C, Mallon E, Venables PJ. Human retrovirus-5 in rheumatic disease. J Autoimmun 1999; 13: 149-54.
17. Osame M, McArthur JC. Neurological manifestations of infection with human T lymphotropic virus type 1. In Asbury AK, Mckhan GM, McDonald WI, eds. Diseases of the nervous system, clinical neurobiology. Vol II. Philadelphia: WB Saunders; 1992. p. 1331-9.
18. Roman GC, Osame M. Identity of HTLV-I associated tropical spastic paraparesis and HTLV-1 associated myelopathy. Lancet 1988; 1: 651.
19. Pradilla G, León-S FE, Zaninovic V. Paraparesia espástica tropical asociada al HTLV-1 en Santander. UIS Salud 1989; 17: 7-15.
20. Izumo S, Umehara F, Osame M. HTLV-I-associated myelopathy. Neuropathology 2000; 20: 65-8.
21. Itoyama Y, Minato SI, Goto I. HTLV-I associated myelopathy (HAM) and seronegative spastic spinal paraparesis (SSP). In Román GC, Vernant JC, Osame M, eds. New York: Alan R. Liss; 1989. p. 209-12.
22. Kira JI, Koyanagi Y, Hamakado T, Itoyama Y, Yamamoto N, Goto I. HTLV-II in patients with HTLV-I associated myelopathy. Lancet 1991; 338: 64-5.
23. León-S FE. Neurofisiología clinica de la PET/HAM. In Zaninovic V, Galindo J, Blank A, eds. Enfermedades asociadas con el virus HTLV-I. Cali: XYZ; 1992. p. 97-102.
24. León-S. FE, Zaninovic V, Arimura K, Arimura Y, Osame M. Subclinical and geographical differences between some of the neurophysiological studies on HAM/TSP from different areas of the world. Rev Med Chile 1994; 122: 265-73.
25. León-S FE, Arimura K, Arimura Y, Sonoda S, Suwazono S, Osame M. A clinical neurophysiological comparative study on HTLV-I associated myelopathy/tropical spastic paraparesis throughout the world. Arch Med Res 1995; 26: 397-403.
26. León-S FE, de Castro-Costa CM, Gaffga N. Discrepancy, coincidence or evidence in chronic idiopathic spastic paraparesis throughout the world. Arq Neuropsiq 1997; 55: 530-5.
27. León-S FE. Un metaanálisis de paraparesia espática tropical y HTLV-I. Acta Med Col 2000; 25: 287.
28. Richardson JH, Newell AL, Newman PK, Mani KS, Rangan G, Dalgleish AG. HTLV-I and neurological disease in South India. Lancet 1989; 1: 709.
29. Carton H. Mielopatías virales y no virales. In Zaninovic V, Castro-Costa CM, eds. La PET/HAM. La paraparesia espástica tropical o mielopatía asociada con el HTLV-I. Cali: Feriva; 1998. p. 1-1.
30. Takatsuki K. Adult T-cell leukemia (ATL): an overview. In Román GC, Vernant JC, Osame M, eds. HTLV-1 and the nervous system. New York: Alan R. Liss; 1989. p. 57-63.
31. Mahe A, Gessain A, Huerre M, Valensi F, Keita S, Bobin P. Leucemie/lymphome T de l'adulte associe au HTLV-1 chez un africain seropositif pour le VIH 2. Ann Dermatol Veneorol 1994; 121: 704-9.
32. Jogessar VB, de Bruyn CC, Bhigjee AI, Naicker VL, Bill PL, Tait D. Adult T-cell leukemia/lymphoma associated with HTLV-1 in Natal. South Afr Med J 1992; 81: 528-9.
33. Shimoyama M. Human T-cell leukemia virus type 1 (HTLV-1) negative adult T-cell leukemia/lymphoma. Hem Rev 1990; 3: 211-22.
34. Gessain A, Gout O, Saal F, Daniel MT, Rio B, Flandrin G, et al. Epidemiology and immunovirology of human T-cell leukemia/lymphoma virus type 1-associated adult T-cell leukemia and chronic myelopathies as seen in France. Cancer Res 1990; 50 (Suppl 17): S5692-6.
35. Harrington WJ Jr, Ucar A, Gill P, Gill P, Snodgrass S, Sheremata W, et al. Clinical spectrum of HTLV-I in South Florida. J AIDS Human Retrovirol 1995; 8: 466-73.
36. Kottilil S, Fram R, Cortez K, Schwartz S, Kesan SH. Hypercalcemia and T-cell lymphoma with acquired immunodeficiency syndrome: occurrence without human T-cell leukemia virus type 1. South Med J 2000; 93: 894-7.
37. Nakagawa M, Izumo S, Ijichi S, Moritoyo T, Higuchi I, Usuku K, et al. HTLV-1 associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1: 50-61.
38. Pancake BA, Zucker-Frnklin D, Coutava SEE. The cutaneous T-cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus associated disease: a study of 50 patients. J Clin Inv 1995; 95: 547-54.
39. Bazarbachi A, Soriano V, Pawson R, Vallejo A, Moudgil T, Matures E, et al. Mycosis fungoides and Sézary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol 1997; 98: 927-33.
40. Bazarbachi A, Saal F, Laroche L, Lasneret J, Gessain A, Daniel MT, et al. HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sézary syndrome. Leukemia 1994; 8: 201-7.
41. Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, et al. Prevalence of serum and salivary antibodies to HTLV-I in Sjögren syndrome. Lancet 1994; 344: 1116-9.
42. Nakamura H, Koji T, Tominaga M, Kawakami A, Migita K, Kawabe Y, et al. Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: comparison with human T lymphotropic virus type I (HTLV-I) seronegative and seropositive SS patients. Clin Exp Immunol 1998; 114: 106-12.
43. Zaninovic V. Reappraisal of HTLV-I associated diseases. In Zaninovic V, ed. HTLV, thruths and questions. Cali: Feriva; 1996. p. 301-13.
44. Kawano F, Tsuda H, Yamaguchi K, Nishimura H, Sanada I, Matsuzaki H, et al. Unusual clinical courses of adult T-cell leukemia in siblings. Cancer 1984; 54: 131-4.
45. Kuroda Y, Yukitake M, Kurohara K, Takashima H, Matsui M. A follow-up on spastic paraparesis in Japanese. HAM/TSP. J Neurol Sci 1995; 132: 174-6.
46. Cartier L, Ramírez E, Galeano H. Familial form of tropical spastic paraparesis. Report of 4 families. Rev Med Child 1998; 126: 419-26.
47. Tamiya S, Matsuoka M, Takemoto S, Shimizu K, Yamaguchi K, Mita S, et al. Adult T cell leukemia following HTLV-I associated myelopathy/ tropical spastic paraparesis: case reports and implication to the natural course of ATL. Leukemia 1995; 9: 1768-70.
48. Schneider BF, Chritian M, Hess CE, Williams ME. Familial occurrence of cutaneous T cell lymphoma: a case report of monozygotic twin sister. Leukemia 1995; 9: 1979-81.
49. Shwartz J, González J, Rosenberg R, Fujihara K, Cottrill CM, Klainer AS, et al. Cutaneous T-cell lymphoma, tropical spastic paraparesis, cerebral vasculitis, and protein S deficiency in a patient with HTLV-I. Southern Med J 1996; 89: 999-1000.
50. Goya K, Murakami A, Koseto M, Tatekawa T, Fujii T, Suzuki T. Adult T-cell leukemia/lymphoma following Sjögren's syndrome. Nippon Naika Gakkai Zasshi 2001; 90: 127-9.
51. Takezako Y, Kanda Y, Arai C, Takezako N, Shirai Y, Hirano N, et al. Spontaneous remission in acute type adult T-cell leukemia/lymphoma. Leuk Lymphoma 2000; 39: 217-22.
52. Goubau P, Desmyter J, Ghesquiere J, Kasereaka B. HTLV-II among pygmies. Nature 1992; 359: 201.
53. Kaplan JE, Khabbaz RF. The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol 1995; 3: 137-48.
54. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive myelopacal disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993; 33: 392-6.
55. Poiesz B, Dube D, Dube S, Love J, Papsidero L, Uner A, et al. HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med 2000; 342: 930-6.
56. Guitart J. HIV-1 and an HTLV-II-associated cutaneous T-cell lymphoma. N Engl J Med 2000; 343: 303-4.
57. Harrington WJ Jr, Sheremata W, Hjelle B, Dube DK, Bradshaw P, Foung SK, et al. Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 1993; 33: 411-4.
58. Zaninovic V, Tajima K, Sonoda S, Miura T. HTLV-II carriers among Colombian amerindians. AIDS Res Hum Retrov 1994; 10: 474.
59. Johnson CH. ¿Es el VIH la causa del sida? Entrevista a Eleni Papadopulos-Eleopulos. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 37-47.
60. Duesberg PH. AIDS: Non-infectious deficiencies acquired by drug consumption and other risk factors. Res Immunol 1990; 141: 5-11.
61. Duesberg PH. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacol Ther 1992; 55: 201-77.
62. Duesberg PH. The HIV gap in national AIDS statistics. Bio/Technology 1993; 11: 955-6.
63. Duesberg PH. Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res 1987; 47: 1199-220.
64. Benítez-Bibriesca L. ¿Son en verdad los VIH los agentes causales del sida? Gac Med Mex 1991; 127: 75-84.
65. Papadopulos-Eleopulos E. Reappraisal of AIDS: is the oxidation caused by the risk factors the primary cause? Med Hypoth 1988; 25: 151-62.
66. León-S Fe, Zaninovic V. Facts, factors and cofactors in the retroviral road. Medicas-UIS 1995; 9: 68-72.
67. Bhigjee AI, Bill PL, Hammond MG. HLA profile and HTLV-1 associated myelopathy (HAM/TSP) in Natal, South Africa. J Neurol Neurosurg Psychiatry 1992; 55: 329-30.
68. Sonoda S, Yashiki S, Kuwayama M, Fijiyoshi T, Jacobson S, Manns A, et al. HLA and HTLV-workshop report. Hum Immunol 1996; 47: 120.
69. Yoshida M, Osame M, Usuku K, Matsumoto M, Igata A. Viruses detected in HTLV-I associated myelopathy and adult T cell leukemia are indentical on DNA blotting. Lancet 1987; 1: 1085-6.
70. Kaplan J, Osame M, Kubota H. The risk of development of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) among persons infected with HTLV-1. J AIDS 1990; 3: 1096-101.
71. Tajima K. The 4th nationwide study of adult T cell leukemia/lymphoma (ATL) in Japan: estimate of risk of ATL and its geographical and clinical features. Int J Cancer 1990; 45: 237-43.
72. Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1996.
73. Schulz TF. KSHV (HHV8) infection. J Infect 2000; 41: 125-9.
74. Di Gennaro G, Canzonieri V, Schioppa O, Nasti G, Carbone A, Tirelli U. Discordant HHV8 detection in a young HIV-negative patient with Kaposi's sarcoma and sarcoidosis. Clin Infect Dis 2001; 32: 1100-2.
75. Bolton WV, Davis AR, Ge YC, Dwyer DE, Kenrick KG, Cunning-ham AL, et al. Molecular evidence for transmission of human T-lymphotropic virus type II infection by a human bite. J Clin Microbiol 1999; 37: 238-40.
76. Zaninovic V. Spastic paraparesis: a possible sexually transmitted viral myeloneuropathy. Lancet 1986; 2: 1031-2.
77. Duesberg P, Rasnick D. The AIDS dilemma: drug diseases blamed on a passenger virus. Genetica 1998; 104: 85-132.
78. Rhodes T, Donoghoe M, Hunter G, Soteri A, Stimson GV. Sexual behaviour of drug injectors in London: implications for HIV transmission and HIV prevention. Addiction 1994; 89: 1085-9.
79. Mackie ID, Gree RD. Possible origin of human AIDS. CMAJ 1985; 133: 547.
80. Sebastian R. Did AIDS start in the jungle? Lancet 1996; 348: 1392.
81. Elm J, Desowitz R, Diwan A. Serological cross-reactivities between the retroviruses HIV and HTLV-I and the malaria parasite Plasmodium falciparum. PNG Med J 1998; 41: 15-22.
82. Srivastava BI, Gonzales C, Loftus R, Fitzpatrick JE, Saxinger CW. Examination of HTLV-I ELISA-positive leukemia/lymphoma patients by western blotting gave mostly negative or indeterminate reaction. AIDS Res Hum Retrov 1990; 6: 617-27.
83. Guitart J, Mahieux R, Horal P, Mauclere P, Mercereau-Puijalon O, Guillotte M, et al. Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection. J Clin Microbiol 2000; 38: 4049-57.
84. Aboulafia DM, Feigal E, Vranzian K, Bennett C, Blattner W, Moss A, et al. Human T cell leukemia virus (HTLV-I/II) serodiagnostic testing: disparate results among a cohort of intravenous drug users. AIDS Res Hum Retrov 1993; 9: 1043-50.
85. Palker TJ, Singer KH, Vahlne A. Characterization of an antigen shared by human thymic epithelium and human T cell leukemia virus p19 Gag protein. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 10-9.
86. Parra E, León-Sarmiento FE, Daza N, Ramírez H, Valderrama V. False-positive HIV tests and Trypanosoma cruzi. [In press].
87. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D. HIV antibodies: further questions and a plea for clarification. Curr Med Res Opin 1997; 13: 627-34.
88. Papadopulos-Eleopulos E, Turner VF, Papadimitiou JM, Causer D, Page BAP. HIV antibody tests and viral load-more unanswered questions and a further plea for clarification. Curr Med Res Opin 1998; 14: 185-6.
89. Alfonso H, León-S FE, Brokate AM. Ciencia basada en la otra evidencia. Parte II: discrepancias e inconsistencias en los modelos epidemiológicos del sida. Neuroc Col 1999; 7: 53-7.
90. Marxl JL. Leukemia virus linked to nerve disease. Science 1987; 236:1059-61.
91. Virus disease: human T lymphotropic virus type I, HTLV-I [editorial]. Who Wkly Epidem Rec 1989; 49: 382-3.
92. Botinas LL, In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 97-107.
93. Giraldo R. AIDS and Stressors. Medellin: Fundacion Arte y Ciencia; 1997.
94. Salemi M, Vandamme AM, Desmyter J, Casoli C, Bertazzoni U. The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy. Gene 1999; 234: 11-21.
95. León-S FE. Rehabilitación y restauración nutricional en neurología. Salud UIS 1998; 26: 11-16.
96. León-S FE, Rivera SA, Vargas EJ, van Bentum A, Grupo ASINO-HIV. Sida en Santander ¿malas interpretaciones, falta de recursos... o qué? Acta Med Col 1998; 23: 243.
97. León-S FE, Prada D, Rodríguez C. Ciencia basada en la otra evidencia. Parte III: priones, infecciones y confusiones en las encefalopatías espongiformes transmisibles. Inv Clin 2000; 41: 189-210.
98. Alfonso H, León-S FE. Ciencia basada en la otra evidencia. Parte I: VIH ¿mito o realidad? Acta Med Cartagena 1999; 6: 157-60.
99. Cartier-Rovirosa L, Mora C, Araya F, Castillo J, Verdugo R, Miller MA, et al. HTLV-I positive spastic paraparesis in a temperate zone. Lancet 1989; 2: 556-7.
100. Barnett TP. Interaction of the monsoon and Pacific trade wind system at interannual time scales. Part III: a partial anatomy of the southern oscillation. Month Weath Rev 1984; 112: 2388-400.
101. León-S FE, Zaninovic V. Climate, culture and cofactors in HAM/TSP in Colombia. Acta Med Col 1994; 19: 248.
102. León-S FE, Zaninovic V. Geographical considerations on HAM/TSP in Japan. Rev Inst Med Trop Sao Paulo 1995; 37: 185-6.
103. Román GC, Román LN. Tropical spastic paraparesis. A clinical study of 50 patients from Tumaco (Colombia) and review of the worldwide features of the syndrome. J Neurol Sci 1988; 87: 121-38.
104. Tajima K, Tominaga S, Kuroishi T, Shimizu H, Suchi T. Geographical features and epidemiological approach to endemic T-cell leukemia/lymphoma in Japan. Jpn J Clin Oncol 1979; 9 (Suppl): 495-504.
105. Yunoki K, Matsumoto M, Matsumoto T. T cell leukemia in Kagoshima: its clinical features and skin lesions. In Hanaoka M, Takatsuki K, Shimoyama M, eds. Adult T cell leukemia and related disease. Tokyo: Japan Scientist Society Press; 1982. p. 151-63.
106. Pittock AB, Whrtton P, Wang Y. Climate and food supply. Nature 1994; 371: 25.
107. León-S FE, Carpintero MI. Neuromicotoxinas, neuromicotoxicosis y neuromicotoxicologia. Acta Med Col 1996; 21: 84-6.
108. Lacey J. Pre and post-harvest ecology of fungi causing spoilage of foods and other stored products. J Appl Bacteriol Symp 1989; (Suppl): 11-25.
109. Schoental R. Kuru, mycotoxins and volcanic eruptions. J Appl Toxicol 1990; 10: 153.
110. León-Sarmiento FE, Uribe M. Micotoxicosis humana: conceptos recientes. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 187-207.
111. León-Sarmiento FE. Refrigeración, retrovirus y mieloneuropatías tropicales: el caso colombiano. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 133-41.
112. Zaninovic V. On the etiology of tropical spastic paraparesis and human T-cell lymphotropic virus-I-associated myelopathy. Int J Infect Dis 1999; 3: 168-76.
113. León-S FE, Carpintero M, Bayona J, Gaffga N, Ocampo L, del Castillo N. La falta de refrigeración y la intoxicación por micotoxinas son cofactores fundamentales en la paraparesia espástica tropical. Rev Neurol 1998; 152: 564-7.
114. León-S FE, Gaffga N. Nutritional rehabilitation in tropical neurology. In Sawhney IMH, Chopra JS, eds. Neurology in Tropics. New Delhi: Churchill Livingstone; 1999. p. 16-23.
115. León-Sarmiento FE, Ocampo L. Neuroteluroepidemiología II: El caso Japonés... y el 'miso' Japonés. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogota: Celsus; 2001. p. 163-75.
116. León-Sarmiento FE, Carpintero M. Neuroteluroepidemiologia III: El caso intertropical y el fenómeno de 'El Niño'. En León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 177-86.
117. Ciegler A, Ajl SJ. Microbial toxins. Vol. VII. New York: Academic Press; 1971. p. 293-316.
118. Miso. An illustrated Encyclopedia. Tokyo: Kodansha; 1993. p. 207-9.
119. Yamazaki M, Horie Y, Suzuki S. On the toxic metabolites of fungi isolated from 'home-made' miso. J Food Hyg Soc Japan 1971; 12: 370-5.
120. Tsuboi S, Nakagawa T, Tomita M, Seo T, Ono H, Kawamura K, et al. Detection of aflatoxin B1 in serum samples of male Japanese subjects by radioimmunoassay and high-performance liquid chromatography. Cancer Res 1984; 44: 1231-4.
121. Seikechi I, Kawahara K, Iwamura N. Aflatoxins in a cup of coffee (A study on aflatoxin B1 in japanese foods). ICMR Ann 1983; 3: 109-15.
122. Saito M, Ishiko T, Enomoto M, Ohtsubo K. Screening test using HeLa cells and mice detection of mycotoxin-producing fungi isolated from food stuff. An additional report on fungi collected in 1968 and 1969. Jap J Exp Med 1974; 44: 63-82.
123. Schoental R. Mycotoxins and the toxicity of plants. Chem Br 1984; 20: 1108-13.
124. Kramer A, Maloney E, Rodgers-Johnson P, Morgan OSC. Risk factors and cofactors for TSP in Jamaica. Proceedings, V international congress on retrovirology. Kumamoto, 1992.
125. Schoental R Reflections on the environmental factors that can modify the action of pyrrolizidine alkaloids. J Appl Toxicol 1991; 11: 75.
126. Burguera JA, Edds GT. Aflatoxin B1 and crotalaria toxicity in turkey poults. Acta Cient Venezol 1984; 35: 67-70.
127. Cliff J, Nicala D, Saute F, Givragy R, Azambuja G, Taela A, et al. Konzo associated with war in Mozambique. Trop Med Int Health 1997; 2: 1068-74.
128. Lancaster PA, Ingram JS, Lim MY, Coursey DG. Traditional cassava-based foods: survey of processing techniques. Econ Botanic 1982; 36: 12-45.
129. Tylleskar T, Banea M, Bikangi N, Nahimana G, Persson LA, Rosling H. Dietary determinants of a non-progressive spastic paraparesis (Konzo): a case-referent study in a high incidence area of Zaire. Int J Epidemiol 1995; 24: 949-56.
130. Banea-Mayambu JP, Tylleskar T, Gitebo N, Matadi N, Gebre-Medhin M, Rosling H. Geographical and seasonal association between linamarin and cyanide exposure from cassava and the upper motor neurone disease Konzo in former Zaire. Trop Med Int Health 1997; 2: 1143-51.
131. Cruickshank EK. Effects of malnutrition on the central nervous system and the nerves. In Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier; 1976. p. 1-41.
132. Jeannel D, Garin B, Kazadi K, Singa L. The risk of tropical spastic paraparesis differs according to ethnic group among HTLV-1 Carriers in Inongo, Zaire. J AIDS 1993; 6: 840-4.
133. Adegoke GO, Babalola AK, Akanni AO. Effects of sodium metabisulphite, hydrogen peroxide and heat on aflatoxin GI in Lafun and Gari, two cassava products. Narhung 1991; 35: 1041-5.
134. Hall JO, Beasley VR. Why these toxins and why now? Vet Hum Toxicol 1990; 32 (Suppl): 1-5.
135. Soares LM, Rodríguez-Amaya DB. Survey of aflatoxins, ochratoxin A, zearalenone, and sterigmatocystin in some Brazilian foods by using multi-toxin thin-layer chromatographic method. J Assoc Off Anal Chem 1989; 72: 22-6.
136. Adegoke GO, Akinnuoye OF, Akanni AO. Effect of processing on the mycoflora and aflatoxin B1 level of a cassava-based product. Plant Foods Hum Nutr 1993; 43: 191-6.
137. Ibeh IN, Uraih N, Ogonor JI. Dietary exposure to aflatoxin in Benin City, Nigeria: a possible public health concern. Int J Food Microbiol 1991; 14: 171-4.
138. Van Rensburg SJ, Kirsipuu A, Coutinho LP, Van Der Watt JJ. Circumstances associated with the contamination of food by aflatoxin in a high primary liver cancer area. S Afr Med J 1975; 49: 877-83.
139. Ali-Shtayeh MS, Salameh AA, Abu-Ghdeib SI, Jamous RM. Hair and scalp mycobiota in school children in Nablus area. Mycopathologia 2001; 150: 127-35.
140. Smallman-Raynor MR, Cliff AD. Seasonality in tropical AIDS: a geographical analysis. Int J Epidemiol 1992; 21: 547-63.
141. Porter S. Maize production, drought and AIDS in Monze District, Zambia. Health Pol Plann 1993; 8: 247-54.
142. Ellison BJ, Downey AB, Duesberg PH. HIV as a surrogate marker for drug use: a re-analysis of the San Francisco men's health study. Genetica 1995; 95: 165-71.
143. Peterson PK, Gekker G, Chao CC, Schut R. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures involvement of transforming growth factor-B. J Immunol 1991; 146: 81-4.
144. Hendrickse RG, Maxwell SM. Heroin addicts, AIDS, and aflatoxins. Br Med Clin Res 1988; 296: 1257.
145. León-S FE. Micotoxinas y la encefaloneuromielopatía cubana. Inv Clin 1999; 40: 161-4.
146. Geshekter CHL, Subdesarrollo, sexo y sida en el África. En León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 33-6.
147. Luna A, Infante F, Dominguez E. Mycoflora of potential sanitary interest present in illicit heroin. Z Rechtsmed 1986; 96: 297-302.
148. Llewellyn GC, O'Rear CE. Examination of fungal growth and aflatoxin production on marihuana. Mycopathologia 1977; 62: 109-12.
149. Nelson AJ, Elías KS, Arévalo E, Darlington LC, Bailey BA. Genetic characterization by RAPD analysis of isolates of Fusarium oxysporum f. sp. Erythroxyli associated with an emerging epidemic in Peru. Phytopathology 1997; 87: 1220-5.
150. Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD, William DC, D'onofrio S, et al. Risk factors for Kaposi's sarcoma in homosexual men. Lancet 1982; 1: 1083-7.
151. Archibald CP, Schechter MT, Le TN, Craib KJ, Montaner JS, O'Shaughnessy MV. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology 1992; 3: 203-9.
152. Bondy GS, Pestka JJ. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev 2000; 3: 109-43.
153. Corrier DE. Mycotoxicosis: mechanisms of immunosupression. Veter Immunol Immunopathol 1991; 30: 73-87.
154. Pestka JJ, Dong W, Warner RL, Rasooly L, Bondy GS. Effect of dietary administration of the trichothecene vomitoxin (deoxynivalenol) on IgA and IgG secretion by Peyer's patch and splenic lymphocytes. Food Chem Toxicol 1990; 28: 693-9.
155. Chu FS. Mycotoxins: food contamination, mechanism, carcinogenic potential and preventive measures. Mut Res 1991; 259: 291-306.
156. Wang E, Norred W, Bacon CW, Riley RT. Inhibition of sphingolipid biosynthesis by fumonisins. J Biol Chem 1991; 266: 1486-90.
157. Schoental R. Mycotoxins, pesticides and the immune system. J Appl Toxicol 1989; 9: 359.
158. León-S FE, Ariza-Deleon A, León ME, Ariza-C A. Peopling the Americas. Science 1996; 273: 723-4.
159. Betina V. Structure activity relationships among mycotoxins. Chem Biol Interact 1989; 71: 105-46.
160. Schaumburg HH, Spencer PS. Recognizing neurotoxic disease. Neurology 1987; 37: 276-8.
161. Brouillet E, Hantmye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995; 92: 7105-9.
162. Wilson EJ, Byerly CS, Burka LT. Neurologic disease of fungal origin of three herds of cattle. JAMA 1979; 5: 480-1.
163. Uribe M, León-S FE. Neurotoxicidad asociada con enfermedad trasmitida por alimentos. In Uribe M, ed. Neurotoxicología. Bogotá: Exlibris; 2001. p. 69-87.
164. León-S FE. Neuromycotoxicosis in the second world war. Can J Neurol Sci 1993; 20: 185.
165. León-S FE. Kuru, volcanoes and viruses: it is not the song, it is the singer. ABC 1995; 2: 81-4.
166. Spencer PS, Ludolph AC, Kisby GE. Neurologic diseases associated with use of plant components with toxic potential. Environ Res 1993; 62: 106-13.
167. Gordon KE, Masotti RE, Waddell WR. Tremorgenic encephalopathy: a role mycotoxins in the production of CNS disease in humans. Can Neurol Sci 1993; 20: 237-9.
168. Schoental R. Neuropathies, mycotoxins and volcanic eruptions. Intern J Environ Stud 1990; 36: 133-6.
169. León-S FE, Acevedo A. El complejo de las tres 'V': Visna, virus y volcanes. Neuroc Col 1998; 6: 25-8.
170. León-S FE. La micotoxicosis humana es una perra vieja con nuevas mañas. Neuroc Col 1998; 6: 47-8.
171. León-S FE, Zaninovic V. Sindrome de neuromicotoxicosis humana: la otra posibilidad en enfermedades neurodegenerativas. Acta Neurol Col 1995; 11: 286-7.
172. León-S FE, Zaninovic Y. Vitamin C (ascorbic acid): new roles, new requirements? Nutr Rev 1994; 52: 188.
173. Shwarz RI. Ascorbate stabilizes the differentiated state and reduces the ability of Rous sarcoma virus to replicate and uniformly transform cell cultures. Am J Clin Nutr 1991; 54: 1247-51.
174. FAO. Food balance sheet 1975-1977 average and per caput food supplies 1961-1965 Average, 1967-1977. Roma; 1980.
175. Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psichiatry 1993; 56: 1213-6.
176. Vimokesant SL, Hilker DM, Nakomacho S, Rungruangsak K, Dhanamitta S. Effects of betel nut and fermented fish on the thiamin status of noreastern Thias. Am J Clin Nutr 1975; 28: 1458-63.
177. Kimbrough RD. Vacuolar myelopathy in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 827.
178. Iwasaki Y, Ohara Y, Kobayashi I, Akizuki S. Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 1992; 140: 1003-8.
179. Cartier LM, Cea JG, Vergara C, Araya F, Born P. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropathol Exp Neurol 1997; 56: 403-13.
180. Liberski PP, Buczynski J, Yanahigara R, Mora C, Gibbs CJ, Gajdusek C, et al. Ultrastructural pathology of a Chilean case of tropical spastic paraparesis/human T-cell lymphotropic type I-associated myelopathy (TSP/HAM). Ultrastruct Pathol 1999; 23: 157-62.
181. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxilation: difference between orientals and caucasians. Br J Clin Pharmacol 1985; 19: 483-7.
182. Marchner H, Tottmar O. A comparative study on the effects of disulfiram, cyanamide and I-amynocyclopropanolol on the acetaldehyde metabolism in rats. Acta Pharmacol Toxicol 1978; 43: 219-32.
183. Tottmar O, Marchner H. Disulfiram as a tool in the studies on the metabolism of acetaldehyde in rats. Acta Pharmacol Toxicol 1976; 38: 366-75.
184. D'Incan M, Souteyrand P, Bignon YJ, Fonck Y, Roger H. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome. Arch Dermatol 1992; 128: 1371-4.
185. Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216-20
186. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: Pharmacogenetics 1995; 5: 255-8.
187. León-Sarmiento FE, Vargas CI. Contactos transpacíficos retrovirales. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 235-55.
188. León-S FE, Ariza-deLeón A, Zaninovic V. The possible transpacific travel of the adult T-cell leukemia virus I. Acta Cient Venez 1996; 47: 140-2.
189. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118-27.
190. Roujeau J, Stem RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
191. Wooldridge WE, Lorenc E. Mycosis fungoides in husband and wife. Mol Med 1985; 82: 201-2.
192. Dupin M, Darie H, Jumbou O, Veran Y, Gros P, Dreno B, et al. Conjugal
193. Sanada I, Yamaguchi K, Yoshida M, Ishii T, Tsukamoto A, Sato M, et al. Adult T-cell leukemia in spouses. Jpn J Cancer Res 1989; 80: 401-4.
194. Lou H, Li HC, Kuwayama M, Fujiyoshi T, Suehara M, Osame M, et al. HLA class I and class II of the Nivkhi, an indigenous population carrying HTLV-I in Sakhalin, Far Eastern Russia. Tissue Antigens 1998; 52: 444-51.
195. León-S FE, Ariza-Deleon A, Ariza-C A. Mitochondrial DNA and some more on the Japanese-South American linkage. South Pacific Study 1994; 15: 9-15.
196. Yamashita M, Veronesi R, Menna-Barreto M, Harrington WJ Jr, Sampio C, Brites C, et al. Molecular epidemiology of human T-cell leukemia virus type I (HTLV-I) Brazil: the predominant HTLV-Is in South America differ from HTLV-Is of Japan and Africa, as well as those of Japanese immigrants and their relatives in Brazil. Virology 1999; 261: 59-69.
197. Wagner HP. Cell cycle control and cancer. Indian J Pediatr 1998; 65: 805-14.
198. Cesarman E, Chadbum A, Inghirami G, Gaidano G, Knowles DM. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205-16.
199. Chen YM, Chen SH, Fu CY, Chen JY, Osame M. Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status. Int J Cancer 1997; 71: 196-202.
200. Gartenhaus RB, Wang P. Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes. Leukemia 1995; 9: 2082-6.
201. Higuchi I, Hashimoto K, Kashio N, Izumo S, Matsuoka H, Nakagawa M, et al. In situ polymerase chain reaction detection of HTLV-I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T-cell leukemia. Acta Neuropathol 1995; 90: 323-7.
202. Nagai H, Kinoshita T, Imamura J, Murakami Y, Hayashi K, Mukai K, Ikeda S, et al. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 1991; 82: 1421-7.
203. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffier HP. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477-80.
204. Xu X, Heindenreich O, Nerenberg M. Role of kinases in HTLV-I transformation. J Invest Med 1996; 44: 113-23.
205. Chen Y-MA, Chen S-H, Fu Ch-Y, Chen J-Y, Osame M. Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I infected people with different clinical status. Int J Cancer 1997; 71: 196-202.
206. Yamato K, Oka T, Hiroi M, Iwahara Y, Sugito S, Tsuchida N, et al. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-I infected cells. Jap J Cancer Res 1993; 84: 4-8.
207. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A, et al. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet 2000; 119: 83-93.
208. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci U S A 2000; 97: 3236-41.
209. Rasnick D, Duesberg PH. How aneuploidy affects metabolic control and causes cancer. Biochem J 1999; 340: 621-30.
210. Shimoyama M. Human T-cell leukemia virus type I and adult T-cell leukemia-lymphoma. Gan To Kagaku. Ryoho 1990; 17: 589-600.
211. León-S FE. Medicina, salud y ciencia... basada en la otra evidencia. In León-Sarmiento FE, ed. ViH y los virus de la imaginación humana. Bogotá: Celsus; 2001. p. 1-3.
212. Giraldo R. Everyone reacts positive on the ELISA tests for HIV. Continuum 1998/9; 5: 8-10.
213. Duesberg PH. Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation. Proc Natl Acad Sci U S A 1989; 86: 755-64.
214. Gadjusek DG. The transmissible dementias and other brain disorders caused by unconventional viruses. Relationship of transmissible to nontransmissibles amyloidosis of the brain. In Kurstak E, Lipowski ZJ, Morozov PV, eds. Virus, immunity and mental disorders. New York: Plenum; 1987. p. 3-22.
215. Pombo de Oliveira MS, Matutes E, Schulz T, Carvalho SM, Noronha H, Reaves JD, et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies on HTLV-I-positive and negative cases. Int J Cancer 1995; 60: 823-7.
216. Zaninovic V, León-S FE. Fifteen years of follow-up on HTLV-I positive and HTLV-I negative spastic paraparesis patients in Southwestern Colombia, Southamerica. J Neurovirol 1996; 2: 357-60.
217. + T-lymphocytopenia without HIV infection. N Engl J Med 1993; 328: 1847-8.
218. Zaninovic V. El virus HTLV-I y la paraparesia espástica tropical. In Zaninovic V, Castro-Costa CM, eds. La PET/HAM. La paraparesia espástica tropical o mielopatía asociada con el HTLV-I. Cali: Feriva; 1998. p. 36-63.
219. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B, aflatoxin B (1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001; 10: 617-25.
220. León-S FE. Bacteria, no!, Fungus, yes! J Clin Epidemiol 1995; 48: 1183.
221. León-S FE. Salmon, ventilation and mycotoxin inhalation. Lancet 1995; 346: 1707.
222. Benítez-Bibriescas L. Alternative medicine: to teach or not to teach. Arch Med Res 2000; 31: 537-8.
223. León-S FE. Un ensayo con las alternativas de la medicina tradicional. Salud UIS 1999; 31: 1-4.
224. Castro-Costa CM, Carton H, Santos TJ. HTLV-1 negative tropical spastic paraparesis: a scientific challenge. Arq Neuropsiquiatr 2001; 59: 289-94.